Pembrolizumab for head and neck cancer

Bookmark and Share
Published: 29 May 2015
Views: 2534
Dr Tanguy Seiwert - University of Chicago, Chicago, USA

Dr Tanguy Seiwert presents the results of a 132-patient study that indicates that pembrolizumab immunotherapy is effective for patients with recurrent or metastatic head and neck cancer (HNC) during a press conference at ASCO 2015.

Read the news article or watch Dr Lynn Schuchter's comment for more.